Gene Therapy of Beta Hemoglobinopathies

Area of Science:

• Hematology
• Genetics
• Molecular Biology

Background:

• Sickle cell disease (SCD) and β-thalassemia are severe genetic blood disorders affecting red blood cells.
• Current treatments are limited, and allogeneic stem cell transplant is only an option for a few patients.

Purpose of the Study:

• To review the advancements in gene therapy for SCD and β-thalassemia.
• To highlight novel therapeutic strategies and their outcomes.

Main Methods:

• This study is a narrative review based on a systematic literature search and analysis.
• Examined gene addition, gene silencing using lentiviral vectors, and gene editing technologies like CRISPR-Cas9 and base editing.

Main Results:

• Autologous hematopoietic stem cell transplantation with ex vivo genetic modification shows promise.
• Gene therapy approaches have achieved durable transfusion independence and corrected hematological abnormalities in patients.
• Several gene therapy products have demonstrated successful clinical evaluation.

Conclusions:

• Approved gene therapy products offer a potentially curative treatment for SCD and β-thalassemia.
• These advanced therapies are transforming patient outcomes and quality of life.